Aura Biosciences Inc. Common Stock AURA · Stock Open Aura Biosciences Inc. Common Stock in new tab
Aura Biosciences Inc. Common Stock Analysis (AURA)
Is Aura Biosciences Inc. Common Stock a good investment? Aura Biosciences Inc. Common Stock (AURA) is currently trading at 6.28 USD. Market analysts have a consensus price target of 18.80 USD. This suggests a potential upside from current levels.
Earnings Schedule: Aura Biosciences Inc. Common Stock is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -2.03.
Investor FAQ
Does Aura Biosciences Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Aura Biosciences Inc. Common Stock?
Aura Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -1.71.
Company Profile
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Community Discussion